Answers are grounded in this paper and cite their sources.
Balancing benefits and risks in the development of treatments for Alzheimer's disease is challenging given the nature of the disease but critically important to ensure effective treatments are available. Drawing on a diverse panel of scientists, regulators, caregivers, patients and advocates convened by the Alzheimer's Association, insights are offered into benefit/risk assessment, decision-making, regulatory and societal factors affecting clinical trials on AD. Several policy solutions are offered to improve the drug testing, review and approval process.
No takes yet. Share an insight, caveat, or question.
McConnell et al. (2006) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: